Skip to content

Wojciech Jurczak

  • MD, PHD, Assoc.Professor
  • The Head of Lymphoma Team
  • Jagiellonian University Medical College
  • 17h-indexImpact measure calculated using publication and citation counts. Updated daily.
  • 1751CitationsNumber of citations received by Wojciech's publications. Updated daily.

Other IDs

Research interests

anti-PD1MoAbIP3 inhibitorsBTK inhibitorslymphoma

Co-authors (483)

Publications (5)

  • Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin's lymphoma

    • Connors J
    • Jurczak W
    • Straus D
    • et al.
    N/AReaders
    1Citations
    Get full text
  • Efficacy and safety of idelalisib in patients with relapsed, rituximab- and alkylating agent-refractory follicular lymphoma: A subgroup analysis of a phase 2 study

    • Salles G
    • Schuster S
    • De Vos S
    • et al.
    N/AReaders
    3Citations
    Get full text
  • Health-related quality of life data from a phase 3, international, randomized, open-label, multicenter study in patients with previously treated mantle cell lymphoma treated with ibrutinib versus temsirolimus

    • Hess G
    • Rule S
    • Jurczak W
    • et al.
    N/AReaders
    0Citations
    Get full text
  • Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial

    • Zelenetz A
    • Barrientos J
    • Brown J
    • et al.
    N/AReaders
    18Citations
    Get full text
  • Rituximab – the first biosimilar monoclonal antibodies in hematooncology

    • Giannopoulos K
    • Wróbel T
    • Jurczak W
    • et al.
    N/AReaders
    0Citations
    Get full text

Professional experience

The Head of Lymphoma Team

Uniwersytet Jagielloński - Collegium Medicum

January 2002 - Present